Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | VNN1 | O95497 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22085375 | 0.94 | USP30 (0.56) | USP30HSD11B1VNN1HPGDRECQL | |
| SCHEMBL24249434 | 0.87 | VNN1 (0.54) | USP30HSD11B1VNN1HPGDRECQL | |
| SCHEMBL13934774 | 0.87 | USP30 (0.59) | USP30HSD11B1VNN1HPGDRECQL | |
| SCHEMBL1780697 | 0.87 | USP30 (0.59) | USP30HSD11B1VNN1HPGDRECQL | |
| SCHEMBL1624330 | 0.87 | USP30 (0.62) | USP30HSD11B1HPGDRECQLJAK2 | |
| SCHEMBL21285788 | 0.87 | HSD11B1 (0.69) | USP30HSD11B1HPGDRECQLJAK2 | |
| SCHEMBL4018727 | 0.87 | USP30 (0.62) | USP30HSD11B1HPGDRECQLJAK2 | |
| SCHEMBL14331976 | 0.87 | USP30 (0.59) | USP30HSD11B1VNN1HPGDRECQL | |
| SCHEMBL654494 | 0.85 | USP30 (0.58) | USP30HSD11B1HPGDRECQLJAK2 | |
| SCHEMBL2499421 | 0.84 | USP30 (0.57) | USP30HSD11B1HPGDRECQLJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| CN-113166117-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113788825-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际有限公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3844161-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-11-09 | — | — | EP | disclosed |
| EP-3891142-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-09-14 | — | — | EP | disclosed |
| CN-113788825-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113166117-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112601748-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际有限公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-04 | — | — | US | disclosed |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-15 | — | — | US | disclosed |
| WO-2020114949-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020043658-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-05 | — | — | WO | disclosed |
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885HSD11B1 221/4885VNN1 23/4885 |
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | USP30 3167/4885HSD11B1 221/4885VNN1 23/4885 |
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885HSD11B1 221/4885VNN1 23/4885 |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | USP30 3167/4885HSD11B1 221/4885VNN1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.